

John H Alexander

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3086825/john-h-alexander-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

284
papers

20,848
citations

67
h-index

141
g-index

311
ext. papers

25,402
ext. citations

10.6
avg, IF

6.26
L-index

#	Paper	IF	Citations
284	Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex.. <i>Circulation</i> , 2022 ,	16.7	5
283	Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 417-427	15.1	2
282	Equipoise in Clinical Trials: Enough Uncertainty in Whose Opinion?. <i>Circulation</i> , 2022 , 145, 943-945	16.7	
281	Associated Factors and Clinical Outcomes in Mechanical Circulatory Support use in Patients Undergoing High Risk On-Pump Cardiac Surgery: Insights from the LEVO-CTS trial.. <i>American Heart Journal</i> , 2022 , 248, 35-35	4.9	
280	Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model.. <i>American Heart Journal</i> , 2022 , 251, 13-13	4.9	0
279	Prophylactic levosimendan in patients with low ejection fraction undergoing coronary artery bypass grafting: A pooled analysis of two multicentre randomised controlled trials. <i>Anaesthesia, Critical Care & Pain Medicine</i> , 2022 , 101107	3	0
278	Transcatheter mitral valve repair for functional mitral regurgitation: Evaluating the evidence. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 162, 1504-1511	1.5	5
277	Rationale and Design of a Randomized Trial Evaluating an External Support Device for Saphenous Vein Coronary Grafts.. <i>American Heart Journal</i> , 2021 , 246, 12-12	4.9	0
276	Age-adjusted D-dimer cutoffs to guide anticoagulation in COVID-19 - Authors' reply. <i>Lancet, The</i> , 2021 , 398, 1304	40	
275	Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 326, 1703-1712	27.4	36
274	Risk for non-home discharge following surgery for ischemic mitral valve disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021 , 162, 1769-1778.e7	1.5	3
273	Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas. <i>Open Heart</i> , 2021 , 8,	3	1
272	The association between coronary graft patency and clinical status in patients with coronary artery disease. <i>European Heart Journal</i> , 2021 , 42, 1433-1441	9.5	10
271	Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2021 , 143, 1215-1223	16.7	1
270	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021 , 14, e009614	6.4	1
269	Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial. <i>Lancet, The</i> , 2021 , 397, 2253-2263	40	150
268	Assessment of North American Clinical Research Site Performance During the Start-up of Large Cardiovascular Clinical Trials. <i>JAMA Network Open</i> , 2021 , 4, e2117963	10.4	0

267	Association between levosimendan, postoperative AKI, and mortality in cardiac surgery: Insights from the LEVO-CTS trial. <i>American Heart Journal</i> , 2021 , 231, 18-24	4.9	4
266	Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction. <i>American Heart Journal</i> , 2021 , 231, 18-24	4.9	16
265	Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators. <i>American Heart Journal</i> , 2021 , 231, 18-24	4.9	2
264	Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2021 , 77, 713-724	15.1	5
263	Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation. <i>Heart</i> , 2021 , 107, 713-720	5.1	5
262	Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 254-264	27.4	157
261	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. <i>CKJ: Clinical Kidney Journal</i> , 2021 , 14, 226-236	4.5	1
260	Antithrombotic Strategies in Patients With Atrial Fibrillation and Percutaneous Coronary Intervention-Reply. <i>JAMA Cardiology</i> , 2021 , 6, 241	16.2	
259	Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. <i>Cardiovascular Research</i> , 2021 ,	9.9	3
258	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2726-2737	15.4	5
257	Randomized clinical trial to evaluate a routine full anticoagulation Strategy in Patients with Coronavirus Infection (SARS-CoV2) admitted to hospital: Rationale and design of the ACTION (AntiCoagulation cOroNavirus)-Coalition IV trial. <i>American Heart Journal</i> , 2021 , 238, 1-11	4.9	10
256	Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial. <i>Circulation</i> , 2021 , 144, 1295-1307	16.7	13
255	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 421-433	15.1	13
254	Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data. <i>European Heart Journal</i> , 2021 ,	9.5	12
253	Efficacy and Safety of Antithrombotic Therapy in Patients With Atrial Fibrillation, Recent Acute Coronary Syndrome, or Percutaneous Coronary Intervention and a History of Heart Failure: Insights From the AUGUSTUS Trial. <i>Journal of the American Heart Association</i> , 2021 , e023143	6	
252	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e018984	6	9
251	Are We At Risk of Depriving Patients Lifesaving Cardiac Surgery?: Implications of the ISCHEMIA Trial for Coronary Artery Bypass Graft Surgery. <i>Circulation</i> , 2020 , 142, 1797-1798	16.7	1
250	Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial. <i>American Heart Journal</i> , 2020 , 236, 48-58	4.9	87

249	Reply: Specifics of Dose Modification in ARISTOTLE. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 128-129	15.1	
248	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2287-2295	15.4	5
247	Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE Trial. <i>Journal of the American College of Cardiology</i> , 2020 , 75, 1145-1155	15.1	19
246	Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS. <i>Circulation</i> , 2020 , 141, 1618-1627	16.7	48
245	Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. <i>Circulation</i> , 2020 , 141, 1384-1392	16.7	36
244	Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 162-171	15.1	17
243	Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve. <i>American Heart Journal</i> , 2020 , 227, 91-99	4.9	19
242	Major Adverse Cardiovascular Events After 12 Months Among Patients With Acute Coronary Syndrome Receiving Loading Doses of Atorvastatin Prior to Planned PCI. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 323, 787-789	27.4	3
241	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: An Updated Network Meta-analysis. <i>JAMA Cardiology</i> , 2020 , 5, 582-589	16.2	34
240	Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial. <i>Journal of Internal Medicine</i> , 2020 , 288, 248-259	10.8	2
239	Interplay between PCI access site, anticoagulant agent, and bleeding: Insights from the REGULATE-PCI randomized trial. <i>American Heart Journal</i> , 2020 , 223, 84-86	4.9	
238	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. <i>Diabetes Care</i> , 2020 , 43, 1803-1812	14.6	20
237	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 ,	6.4	2
236	A systematic review of randomized trials comparing double versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020 , 96, E102-E109	2.7	4
235	Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial. <i>European Journal of Preventive Cardiology</i> , 2020 , 27, 1311-1319	3.9	1
234	Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2020 , 221, 1-8	4.9	10
233	Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial. <i>Circulation</i> , 2020 , 141, 781-783	16.7	48
232	Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA trial. <i>Diabetology International</i> , 2020 , 11, 129-141	2.3	13

231	Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation: Findings from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2020 , 302, 53-58	3.2	2
230	Clinical Considerations Prior to Transition From Triple Antithrombotic Therapy to Dual Antithrombotic Therapy-Reply. <i>JAMA Cardiology</i> , 2020 , 5, 111-112	16.2	1
229	Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial. <i>Circulation</i> , 2020 , 141, 10-20	16.7	11
228	Management of Atrial Fibrillation in Older Patients by Morbidity Burden: Insights From Get With The Guidelines-Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e017024	6	13
227	Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. <i>New England Journal of Medicine</i> , 2020 , 383, 2117-2126	59.2	67
226	Outcomes following revascularization with radial artery bypass grafts: Insights from the PREVENT-IV trial. <i>American Heart Journal</i> , 2020 , 228, 91-97	4.9	
225	Sex-related differences in outcomes after coronary artery bypass surgery-A patient-level pooled analysis of randomized controlled trials: rationale and study protocol. <i>Journal of Cardiac Surgery</i> , 2020 , 35, 2754-2758	1.3	2
224	Randomized Trials Versus Common Sense and Clinical Observation: JACC Review Topic of the Week. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 580-589	15.1	22
223	Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2020 , 9, e017155	6	4
222	Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. <i>JAMA Network Open</i> , 2020 , 3, e2015943	10.4	2
221	Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 159, 2230-2240.e15	1.5	4
220	Levosimendan in patients with reduced left ventricular function undergoing isolated coronary or valve surgery. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 , 159, 2302-2309.e6	1.5	21
219	Association Between Delays in Mechanical Ventilation Initiation and Mortality in Patients With Refractory Cardiogenic Shock. <i>JAMA Cardiology</i> , 2020 , 5, 965-967	16.2	9
218	Characteristics and Outcomes of Atrial Fibrillation in Patients With Thyroid Disease (from the ARISTOTLE Trial). <i>American Journal of Cardiology</i> , 2019 , 124, 1406-1412	3	7
217	Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1921-1932	16.7	40
216	Hospitalization Among Patients With Atrial Fibrillation and a Recent Acute Coronary Syndrome or Percutaneous Coronary Intervention Treated With Apixaban or Aspirin: Insights From the AUGUSTUS Trial. <i>Circulation</i> , 2019 , 140, 1960-1963	16.7	6
215	Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials. <i>American Heart Journal</i> , 2019 , 218, 110-122	4.9	7
214	Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials. <i>JAMA Cardiology</i> , 2019 , 4, 747-755	16.2	130

213	Navigating the treacherous waters of antithrombotic therapies in patients with atrial fibrillation and coronary artery disease: Lessons from AUGUSTUS. <i>European Journal of Internal Medicine</i> , 2019 , 65, 4-5	3.9	4
212	Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 2427-2435	15.1	12
211	International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 27-34	5.1	4
210	Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2019 , 380, 1509-1524	59.2	538
209	Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial. <i>Clinical Cardiology</i> , 2019 , 42, 568-573	7.1	43
208	Interacting medication use and the treatment effects of apixaban versus warfarin: results from the ARISTOTLE Trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 47, 345-352	5.1	8
207	Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2019 , 215, 106-113	4.9	5
206	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019 , 7, 618-628	18.1	120
205	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019 , 139, 2292-2300	16.7	47
204	Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation. <i>Heart</i> , 2019 , 105, 235-242	5.1	11
203	Comparison of Outcomes and Frequency of Graft Failure With Use of Free Versus In Situ Internal Mammary Artery Bypass Conduits (from the PREVENT IV Trial). <i>American Journal of Cardiology</i> , 2019 , 123, 571-575	3	4
202	Longitudinal Changes in Regional Cerebral Perfusion and Cognition After Cardiac Operation. <i>Annals of Thoracic Surgery</i> , 2019 , 107, 112-118	2.7	7
201	Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials. <i>Circulation</i> , 2019 , 139, 863-873	16.7	8
200	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. <i>Circulation</i> , 2019 , 139, 351-361	16.7	103
199	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 69-79	27.4	562
198	Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2019 , 208, 123-131	4.9	35
197	The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. <i>American Heart Journal</i> , 2019 , 208, 81-90	4.9	16
196	Digoxin and Mortality in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2018 , 71, 1063-1074	15.1	99

195	Stroke prevention in atrial fibrillation: re-defining 'real-world data' within the broader data universe. <i>European Heart Journal</i> , 2018 , 39, 2932-2941	9.5	19
194	The Clinical Trials Transformation Initiative: Looking back, looking forward. <i>Clinical Trials</i> , 2018 , 15, 3-4	2.2	1
193	Dual antiplatelet therapy for perioperative myocardial infarction following CABG surgery. <i>American Heart Journal</i> , 2018 , 199, 150-155	4.9	0
192	Clinical trials evaluating red blood cell transfusion thresholds: An updated systematic review and with additional focus on patients with cardiovascular disease. <i>American Heart Journal</i> , 2018 , 200, 96-101	4.9	74
191	Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis. <i>JAMA Cardiology</i> , 2018 , 3, 234-241	16.2	30
190	Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) Trial. <i>Journal of the American Heart Association</i> , 2018 , 9, e011777	6	28
189	Antithrombotic therapy use and clinical outcomes following thrombo-embolic events in patients with atrial fibrillation: insights from ARISTOTLE. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 75-81	6.4	4
188	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. <i>European Heart Journal</i> , 2018 , 39, 477-485	9.5	63
187	Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. <i>Heart</i> , 2018 , 104, 1292-1299	5.1	12
186	Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. <i>American Heart Journal</i> , 2018 , 198, 129-134	4.9	3
185	Rationale, design, and baseline characteristics of the Cardiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. <i>Cardiovascular Diabetology</i> , 2018 , 17, 30	8.7	57
184	An open-Label, 2 X 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. <i>American Heart Journal</i> , 2018 , 200, 17-22	4.9	56
183	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. <i>Journal of Thrombosis and Thrombolysis</i> , 2018 , 45, 469-476	5.1	9
182	Effect of Loading Dose of Atorvastatin Prior to Planned Percutaneous Coronary Intervention on Major Adverse Cardiovascular Events in Acute Coronary Syndrome: The SECURE-PCI Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 1331-1340	27.4	64
181	Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. <i>American Heart Journal</i> , 2018 , 197, 1-8	4.9	5
180	Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 721-733	15.1	21
179	Incidence, timing, and type of first and recurrent ischemic events in patients with and without peripheral artery disease after an acute coronary syndrome. <i>American Heart Journal</i> , 2018 , 201, 25-32	4.9	6
178	Crowdsourcing consensus: proposal of a novel method for assessing accuracy in echocardiography interpretation. <i>International Journal of Cardiovascular Imaging</i> , 2018 , 34, 1725-1730	2.5	1

177	Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. <i>Circulation</i> , 2018 , 138, 1666-1676	16.7	23
176	Cost-Effectiveness of Mitral Valve Repair Versus Replacement for Severe Ischemic Mitral Regurgitation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018 , 11,	5.8	5
175	Task-related changes in degree centrality and local coherence of the posterior cingulate cortex after major cardiac surgery in older adults. <i>Human Brain Mapping</i> , 2018 , 39, 985-1003	5.9	13
174	Secondary surgical-site infection after coronary artery bypass grafting: A multi-institutional prospective cohort study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018 , 155, 1555-1562.e1	1.5	16
173	Percutaneous coronary intervention and antiplatelet therapy in patients with atrial fibrillation receiving apixaban or warfarin: Insights from the ARISTOTLE trial. <i>American Heart Journal</i> , 2018 , 197, 133-141	4.9	16
172	Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2018 , 131, 269-275.e2-4	2.4	60
171	Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trial. <i>Open Heart</i> , 2018 , 5, e000908	3	4
170	Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2018 , 3, 1113-1118	16.2	13
169	Long-term outcomes of mitral regurgitation by type and severity. <i>American Heart Journal</i> , 2018 , 203, 39-48	4.9	9
168	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	25
167	Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2017 , 185, 140-149	4.9	31
166	Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome. <i>Annals of Thoracic Surgery</i> , 2017 , 104, 98-105	2.7	6
165	The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review. <i>JAMA Cardiology</i> , 2017 , 2, 324-331	16.2	23
164	Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. <i>Heart</i> , 2017 , 103, 623-628	5.1	30
163	Obesity, Diabetes, and Acute Coronary Syndrome: Differences Between Asians and Whites. <i>American Journal of Medicine</i> , 2017 , 130, 1170-1176	2.4	6
162	Enhancing Insights into Pulmonary Vascular Disease through a Precision Medicine Approach. A Joint NHLBI-Cardiovascular Medical Research and Education Fund Workshop Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 195, 1661-1670	10.2	38
161	Dabigatran Compared With Rivaroxaban vs Warfarin. <i>JAMA Internal Medicine</i> , 2017 , 177, 742-743	11.5	1
160	Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect. <i>Cardiovascular Drugs and Therapy</i> , 2017 , 31, 295-301	3.9	2

159	Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	5
158	Pneumonia after cardiac surgery: Experience of the National Institutes of Health/Canadian Institutes of Health Research Cardiothoracic Surgical Trials Network. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017 , 153, 1384-1391.e3	1.5	45
157	Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2017 , 2, 525-534	16.2	13
156	Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy. <i>Blood</i> , 2017 , 129, 2980-2987	2.2	70
155	Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. <i>American Heart Journal</i> , 2017 , 187, 194-203	4.9	15
154	Association between CK-MB Area Under the Curve and Tranexamic Acid Utilization in Patients Undergoing Coronary Artery Bypass Surgery. <i>Journal of Thrombosis and Thrombolysis</i> , 2017 , 43, 446-453	5.1	2
153	Levosimendan in Patients with Left Ventricular Dysfunction Undergoing Cardiac Surgery. <i>New England Journal of Medicine</i> , 2017 , 376, 2032-2042	59.2	156
152	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017 , 48, 3266-3273	6.7	13
151	Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trial-rationale and study protocol. <i>European Journal of Cardio-thoracic Surgery</i> , 2017 , 52, 1031-1040	3	72
150	Efficacy and Safety of Apixaban Versus Warfarin in Patients with Atrial Fibrillation and a History of Cancer: Insights from the ARISTOTLE Trial. <i>American Journal of Medicine</i> , 2017 , 130, 1440-1448.e1	2.4	83
149	Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	15
148	Anticoagulation therapy and clinical outcomes in patients with recently diagnosed atrial fibrillation: Insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2017 , 227, 443-449	3.2	2
147	Resting-State Functional Connectivity and Cognition After Major Cardiac Surgery in Older Adults without Preoperative Cognitive Impairment: Preliminary Findings. <i>Journal of the American Geriatrics Society</i> , 2017 , 65, e6-e12	5.6	46
146	Nonsteroidal Anti-Inflammatory Drugs and Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Surgery. <i>American Journal of Medicine</i> , 2017 , 130, 462-468	2.4	11
145	Inhibition of factor IXa by the pegnivacogin system during cardiopulmonary bypass: a potential substitute for heparin. A study in baboons. <i>European Journal of Cardio-thoracic Surgery</i> , 2016 , 49, 682-9	3	7
144	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , 2016 , 134, 1697-1707	16.7	58
143	Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. <i>American Heart Journal</i> , 2016 , 180, 22-8	4.9	23
142	Pre-existing anti-PEG antibodies are associated with severe immediate allergic reactions to pegnivacogin, a PEGylated aptamer. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 138, 1712-1715	11.5	104

141	Levosimendan in patients with left ventricular systolic dysfunction undergoing cardiac surgery on cardiopulmonary bypass: Rationale and study design of the Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. <i>American Heart Journal</i> , 2016 , 182, 62-71	4.9	20
140	Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 673-81	16.2	59
139	Impact of Left Ventricular to Mitral Valve Ring Mismatch on Recurrent Ischemic Mitral Regurgitation After Ring Annuloplasty. <i>Circulation</i> , 2016 , 134, 1247-1256	16.7	45
138	Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. <i>BMJ, The</i> , 2016 , 353, i2868	5.9	86
137	REGULATE-PCI trial--Author's reply. <i>Lancet, The</i> , 2016 , 387, 1510-1511	4.0	
136	Response to Letters Regarding Article, "Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial". <i>Circulation</i> , 2016 , 133, e665	16.7	0
135	Pre-existing anti-polyethylene glycol antibody linked to first-exposure allergic reactions to pegnivacogin, a PEGylated RNA aptamer. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 1610-1613.e7	11.5	168
134	Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 451-60	16.2	100
133	Frequency and Predictors of Internal Mammary Artery Graft Failure and Subsequent Clinical Outcomes: Insights From the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial. <i>Circulation</i> , 2016 , 133, 131-8	16.7	51
132	Sudden Cardiac Death After Non-ST-Segment Elevation Acute Coronary Syndrome. <i>JAMA Cardiology</i> , 2016 , 1, 73-9	16.2	13
131	Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation. <i>Heart</i> , 2016 , 102, 508-17	5.1	51
130	History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2016 , 175, 175-83	4.9	10
129	Pooled analysis of adverse event collection from 4 acute coronary syndrome trials. <i>American Heart Journal</i> , 2016 , 174, 60-7	4.9	3
128	The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. <i>European Heart Journal</i> , 2016 , 37, 1582-90	9.5	235
127	Effect of the REG1 anticoagulation system versus bivalirudin on outcomes after percutaneous coronary intervention (REGULATE-PCI): a randomised clinical trial. <i>Lancet, The</i> , 2016 , 387, 349-356	4.0	87
126	Clopidogrel use After Myocardial Revascularization: Prevalence, Predictors, and One-Year Survival Rate. <i>Brazilian Journal of Cardiovascular Surgery</i> , 2016 , 31, 106-14	1.1	3
125	Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I). <i>Circulation</i> , 2016 , 134, 1918-1930	16.7	110
124	Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2016 , 374, 1954-64	59.2	101

123	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , 2016 , 387, 2302-2311	40	272
122	The 'obesity paradox' in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. <i>European Heart Journal</i> , 2016 , 37, 2869-2878	9.5	144
121	Trends in Enrollment, Clinical Characteristics, Treatment, and Outcomes According to Age in Non-ST-Segment-Elevation Acute Coronary Syndromes Clinical Trials. <i>Circulation</i> , 2016 , 133, 1560-73	16.7	15
120	Using Data to Guide Anticoagulation in Patients With Atrial Fibrillation: Does the Analysis Fit the Question?. <i>JAMA Cardiology</i> , 2016 , 1, 121-2	16.2	1
119	Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , 2016 , 375, e22	59.2	16
118	Relation of Post-Coronary Artery Bypass Graft Creatine Kinase-MB Elevations and New Q Waves With Long-Term Cardiovascular Death in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease. <i>American Journal of Cardiology</i> , 2016 , 118, 1655-1660	3	2
117	Management and outcomes in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction. <i>European Heart Journal</i> , 2015 , 36, 2733-41	9.5	39
116	The future of cardiovascular clinical research in North America and beyond-addressing challenges and leveraging opportunities through unique academic and grassroots collaborations. <i>American Heart Journal</i> , 2015 , 169, 743-50	4.9	14
115	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015 , 101, 1475-84	5.1	10
114	Response to letter regarding article, "surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience". <i>Circulation</i> , 2015 , 131, e378-9	16.7	1
113	Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Circulation</i> , 2015 , 132, 624-32	16.7	159
112	Outcomes after nonemergent electrical cardioversion for atrial arrhythmias. <i>American Journal of Cardiology</i> , 2015 , 115, 1407-14	3	5
111	Predictors of long-term clinical endpoints in patients with refractory angina. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	49
110	Sex-Stratified Trends in Enrollment, Patient Characteristics, Treatment, and Outcomes Among Non-ST-Segment Elevation Acute Coronary Syndrome Patients: Insights From Clinical Trials Over 17 Years. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015 , 8, 357-67	5.8	26
109	Apixaban Plus Mono Versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Insights From the APPRAISE-2 Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 777-787	15.1	31
108	The Preservation and Handling of Vein Grafts in Current Surgical Practice: Findings of a Survey Among Cardiovascular Surgeons of Top-Ranked US Hospitals. <i>JAMA Surgery</i> , 2015 , 150, 681-3	5.4	9
107	Genome-wide association study of perioperative myocardial infarction after coronary artery bypass surgery. <i>BMJ Open</i> , 2015 , 5, e006920	3	11
106	Meta-analysis of intracranial hemorrhage in acute coronary syndromes: incidence, predictors, and clinical outcomes. <i>Journal of the American Heart Association</i> , 2015 , 4, e001512	6	12

105	Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>American Heart Journal</i> , 2015 , 169, 25-30	4.9	51
104	Long-term clinical and angiographic outcomes in patients with diabetes undergoing coronary artery bypass graft surgery: results from the Project of Ex-vivo Vein Graft Engineering via Transfection IV trial. <i>American Heart Journal</i> , 2015 , 169, 175-84	4.9	16
103	Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2015 , 36, 1264-72	9.5	99
102	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015 , 1, 86-94	6.4	44
101	Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>Journal of the American Heart Association</i> , 2015 , 4,	6	46
100	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015 , 36, 3268-75	9.5	30
99	Response to Letters Regarding Article, "Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery: Insights From PREVENT IV". <i>Circulation</i> , 2015 , 132, e29	16.7	3
98	Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , 2015 , 4, e002171	6	69
97	Costs associated with health-care-associated infections in cardiac surgery. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 15-23	15.1	42
96	Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the Apixaban for Prevention of Acute Ischemic Events 2 trial. <i>American Heart Journal</i> , 2015 , 169, 531-8	4.9	6
95	Comparison of cardiac troponins I and T measured with high-sensitivity methods for evaluation of prognosis in atrial fibrillation: an ARISTOTLE substudy. <i>Clinical Chemistry</i> , 2015 , 61, 368-78	5.5	29
94	Abstract 17277: Apixaban Use in Patients With Atrial Fibrillation With Bioprosthetic Valves: Insights From ARISTOTLE. <i>Circulation</i> , 2015 , 132,	16.7	11
93	Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 2141-2147	15.1	260
92	High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Circulation</i> , 2014 , 129, 625-34	16.7	86
91	High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 52-61	15.1	114
90	Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1082-7	15.1	189
89	Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. <i>Circulation</i> , 2014 , 130, 1847-58	16.7	188
88	Reply: To PMID 24360877. <i>Annals of Thoracic Surgery</i> , 2014 , 98, 1890	2.7	

87	Surgical treatment of moderate ischemic mitral regurgitation. <i>New England Journal of Medicine</i> , 2014 , 371, 2178-88	59.2	269
86	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014 , 35, 224-32	9.5	118
85	Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV. <i>Circulation</i> , 2014 , 130, 1445-51	16.7	138
84	Readmissions after cardiac surgery: experience of the National Institutes of Health/Canadian Institutes of Health research cardiothoracic surgical trials network. <i>Annals of Thoracic Surgery</i> , 2014 , 98, 1274-80	2.7	66
83	Clinical outcomes of hybrid coronary revascularization versus coronary artery bypass surgery in patients with diabetes mellitus. <i>American Heart Journal</i> , 2014 , 168, 471-8	4.9	18
82	Impact of extracardiac vascular disease on vein graft failure and outcomes after coronary artery bypass surgery. <i>Annals of Thoracic Surgery</i> , 2014 , 97, 824-30	2.7	10
81	Surgical revascularization is associated with maximal survival in patients with ischemic mitral regurgitation: a 20-year experience. <i>Circulation</i> , 2014 , 129, 2547-56	16.7	70
80	Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. <i>American Heart Journal</i> , 2014 , 168, 303-9	4.9	101
79	Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. <i>Blood</i> , 2014 , 124, 3692-8	2.2	124
78	Endoscopic harvesting device type and outcomes in patients undergoing coronary artery bypass surgery. <i>Annals of Surgery</i> , 2014 , 260, 402-8	7.8	14
77	Response to letter regarding article, "Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation". <i>Circulation</i> , 2014 , 129, e21-2	16.7	1
76	Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial. <i>JAMA Surgery</i> , 2014 , 149, 798-805	5.4	52
75	Warfarin use and long-term outcomes in patients with acute myocardial infarction and atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014 , 37, 331-7	5.1	4
74	Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. <i>EuroIntervention</i> , 2014 , 10, 431-8	3.1	22
73	Relationship between postoperative clopidogrel use and subsequent angiographic and clinical outcomes following coronary artery bypass grafting. <i>Journal of Thrombosis and Thrombolysis</i> , 2013 , 36, 384-93	5.1	10
72	Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. <i>International Journal of Cardiology</i> , 2013 , 170, 215-20	3.2	44
71	Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2013 , 27, 1224-32	2.1	80
70	Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>Circulation: Heart Failure</i> , 2013 , 6, 451-60	7.6	106

69	Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. <i>American Heart Journal</i> , 2013 , 166, 549-58	4.9	35
68	Documentation of study medication dispensing in a prospective large randomized clinical trial: experiences from the ARISTOTLE Trial. <i>American Heart Journal</i> , 2013 , 166, 559-65	4.9	7
67	Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. <i>Circulation</i> , 2013 , 127, 2166-76	16.7	164
66	The safety and efficacy of apixaban : where do we stand in 2013?. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 559-67	4.1	2
65	Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. <i>European Heart Journal</i> , 2013 , 34, 2464-71	9.5	127
64	A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. <i>European Heart Journal</i> , 2013 , 34, 2481-9	9.5	70
63	New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2013 , 34, 1670-80	9.5	151
62	Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions. <i>Annals of Surgery</i> , 2013 , 257, 824-33	7.8	219
61	Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. <i>Lancet Neurology</i> , 2012 , 11, 503-11	24.1	212
60	Design, rationale, and initiation of the Surgical Interventions for Moderate Ischemic Mitral Regurgitation Trial: a report from the Cardiothoracic Surgical Trials Network. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2012 , 143, 111-7, 117.e1	1.5	21
59	Promise of factor Xa inhibition in atrial fibrillation. <i>Current Cardiology Reports</i> , 2012 , 14, 70-8	4.2	2
58	Association between endoscopic vs open vein-graft harvesting and mortality, wound complications, and cardiovascular events in patients undergoing CABG surgery. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 475-84	27.4	67
57	Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial. <i>Lancet</i> , 2012 , 380, 1749-58	40	150
56	Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2012 , 33, 2821-30	9.5	400
55	Authors' reply to "The not so ideal body weight-based dosing of Integrilin in obesity". <i>American Heart Journal</i> , 2012 , 163, e25	4.9	0
54	Edifoligide and long-term outcomes after coronary artery bypass grafting: PProject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT IV) 5-year results. <i>American Heart Journal</i> , 2012 , 164, 379-386.e1	4.9	33
53	Novel oral anticoagulants after acute coronary syndromes. <i>Cardiovascular Drugs and Therapy</i> , 2012 , 26, 265-71	3.9	
52	Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysis. <i>American Journal of Cardiology</i> , 2012 , 109, 320-6	3	21

51	Relationship between vein graft failure and subsequent clinical outcomes after coronary artery bypass surgery. <i>Circulation</i> , 2012 , 125, 749-56	16.7	98
50	Apixaban with antiplatelet therapy after acute coronary syndrome. <i>New England Journal of Medicine</i> , 2011 , 365, 699-708	59.2	765
49	A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. <i>American Heart Journal</i> , 2011 , 161, 261-268.e1-2	4.9	29
48	The kinetics of integrilin limited by obesity: a multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. <i>American Heart Journal</i> , 2011 , 162, 996-1002	4.9	3
47	Race, Bleeding, and Outcomes in STEMI Patients Treated with Fibrinolytic Therapy. <i>American Journal of Medicine</i> , 2011 , 124, 48-57	2.4	28
46	Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients: RADAR pharmacokinetic and pharmacodynamic substudy. <i>European Heart Journal</i> , 2011 , 32, 2412-9	9.5	33
45	Apixaban versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , 2011 , 365, 981-92	59.2	5856
44	Antiarrhythmic drug therapy for sustained ventricular arrhythmias complicating acute myocardial infarction. <i>Critical Care Medicine</i> , 2011 , 39, 78-83	1.4	58
43	Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14-16, 2010, Sã Paulo, Brazil. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 32, 242-66	5.1	2
42	Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 585-91	27.4	178
41	Saphenous vein grafts with multiple versus single distal targets in patients undergoing coronary artery bypass surgery: one-year graft failure and five-year outcomes from the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV trial. <i>Circulation</i> , 2011 , 124, 280-8	16.7	86
40	Thrombomodulin gene variants are associated with increased mortality after coronary artery bypass surgery in replicated analyses. <i>Circulation</i> , 2011 , 124, S143-8	16.7	31
39	Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2010 , 104, 976-83	7	50
38	First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. <i>Circulation</i> , 2010 , 122, 614-22	16.7	73
37	Apixaban for reduction in stroke and other Thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <i>American Heart Journal</i> , 2010 , 159, 331-9	4.9	345
36	Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. <i>Circulation</i> , 2009 , 119, 2877-85	16.7	371
35	Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. <i>New England Journal of Medicine</i> , 2009 , 361, 235-44	59.2	264
34	Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PROject of Ex-vivo Vein graft ENGINEERING via Transfection IV (PREVENT-IV) Trial. <i>American Heart Journal</i> , 2009 , 158, 792-8	4.9	34

33	The current state of antiplatelet therapy in acute coronary syndromes: the data and the real world. <i>Cleveland Clinic Journal of Medicine</i> , 2009 , 76 Suppl 1, S16-23	2.8	10
32	Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PROject of Ex-vivo Vein graft ENGINEERING via Transfection [PREVENT] IV). <i>American Journal of Cardiology</i> , 2008 , 102, 546-51	3	54
31	A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II—study design and rationale. <i>American Heart Journal</i> , 2008 , 155, 600-8	4.9	5
30	Clopidogrel Treatment and the MEND-CABG II TrialReply. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 1021	27.4	
29	Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1777-87	27.4	29
28	Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. <i>Circulation</i> , 2008 , 117, 2865-74	16.7	107
27	Antithrombotic therapy in atrial fibrillation: guidelines translated for the clinician. <i>Journal of Thrombosis and Thrombolysis</i> , 2008 , 26, 167-74	5.1	11
26	Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. <i>European Heart Journal</i> , 2007 , 28, 425-32	9.5	16
25	Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 1657-66	27.4	247
24	Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery. <i>Annals of Thoracic Surgery</i> , 2007 , 83, 993-1001	2.7	76
23	First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activity. <i>Circulation</i> , 2006 , 114, 2490-7	16.7	177
22	Time course of degradation of cardiac troponin I in patients with acute ST-elevation myocardial infarction: the ASSENT-2 troponin substudy. <i>Circulation Research</i> , 2006 , 99, 1141-7	15.7	38
21	Elevated creatine kinase-MB with normal creatine kinase predicts worse outcomes in patients with acute coronary syndromes: results from 4 large clinical trials. <i>American Heart Journal</i> , 2006 , 151, 16-24	4.9	19
20	Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. <i>American Heart Journal</i> , 2005 , 149, 670-4	4.9	78
19	The PROject of Ex-vivo Vein graft ENGINEERING via Transfection IV (PREVENT IV) trial: study rationale, design, and baseline patient characteristics. <i>American Heart Journal</i> , 2005 , 150, 643-9	4.9	45
18	Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 294, 2446-54	27.4	442
17	Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy. <i>American Journal of Cardiology</i> , 2005 , 95, 1371-5	3	1
16	Relation of early saphenous vein graft failure to outcomes following coronary artery bypass surgery. <i>American Journal of Cardiology</i> , 2005 , 96, 1254-9	3	89

15	Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes. <i>JAMA - Journal of the American Medical Association</i> , 2005 , 293, 1746-50	27.4	17
14	Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3). <i>American Journal of Cardiology</i> , 2004 , 94, 279-83	3	19
13	Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2004 , 43, 2153-9	15.1	45
12	Feasibility of point-of-care echocardiography by internal medicine house staff. <i>American Heart Journal</i> , 2004 , 147, 476-81	4.9	117
11	Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. <i>American Heart Journal</i> , 2004 , 147, 993-8	4.9	28
10	Integrating antithrombin and antiplatelet therapies with early invasive management for non-ST-segment elevation acute coronary syndromes. <i>American Journal of Medicine</i> , 2004 , 116, 119-29	2.4	3
9	Effect of tenecteplase versus alteplase on platelets during the first 3 hours of treatment for acute myocardial infarction: the Assessment of the Safety and Efficacy of a New Thrombolytic Agent (ASSENT-2) platelet substudy. <i>American Heart Journal</i> , 2003 , 145, 636-42	4.9	23
8	Safety of the weight-adjusted dosing regimen of tenecteplase in the ASSENT-Trial. <i>American Journal of Cardiology</i> , 2001 , 88, 1240-5	3	16
7	Platelets and Thrombolysis: Cooperation or Contrariety?. <i>Cardiology</i> , 2001 , 1, 281-290		4
6	Medicine. Placebo-controls in short-term clinical trials of hypertension. <i>Science</i> , 2001 , 292, 2013-5	33.3	27
5	Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2000 , 283, 347-53	27.4	67
4	Highlights from the American Heart Association 72nd scientific sessions: November 6 to 10, 1999. <i>American Heart Journal</i> , 2000 , 139, 359-370	4.9	10
3	The clinical use of an esophageal Doppler monitor for hemodynamic monitoring in sepsis. <i>Journal of Clinical Monitoring and Computing</i> , 1999 , 15, 223-5	2	12
2	Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. <i>American Heart Journal</i> , 1999 , 137, 792-8	4.9	84
1	Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. <i>American Heart Journal</i> , 1999 , 137, 799-805	4.9	53